Work

Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms

Year: 2020

Type: article

Source: Leukemia

DOI: 10.1038/s41375-020-0858-1

Authors: Ami B. Patel, Anthony D. Pomicter, Dongqing Yan, Anna M. Eiring, Orlando Antelope, Jonathan A. Schumacher, Todd W. Kelley, Srinivas K. Tantravahi, Tibor J. Kovacsovics, Paul J. Shami, Thomas O’Hare, Michael W. Deininger

Institutions: University of Utah, Huntsman Cancer Institute, Texas Tech University Health Sciences Center, ARUP Laboratories (United States)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: U.S. Department of Health and Human Services, V Foundation for Cancer Research, American Society of Hematology, Lady Tata Memorial Trust, National Institutes of Health, National Cancer Institute, National Center for Research Resources

Awards: G0S2 in Chronic Myeloid Leukemia Disease Progression and Imatinib Resistance, G2636606427, G3022364995, G3347820046, G368171078, G4190287910, Mechanisms of resistance to ponatinib therapy in chronic myeloid leukemia, G7292015657, G858682239, G906742146

OpenAlex ID: W3025728513

FWCI: 0.944

Cites: 62

Cited by: 15

Related to: 10